Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
Identifieur interne : 003020 ( PubMed/Corpus ); précédent : 003019; suivant : 003021Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
Auteurs : Sven Mahner ; Werner Meier ; Andreas Du Bois ; Chris Brown ; Domenica Lorusso ; Tiziana Dell'Anna ; Jacques Cretin ; Hanne Havsteen ; Paul Bessette ; Alain G. Zeimet ; Ignace Vergote ; Paul Vasey ; Eric Pujade-Lauraine ; Laurence Gladieff ; Annamaria FerreroSource :
- European journal of cancer (Oxford, England : 1990) [ 1879-0852 ] ; 2015.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Carboplatin (administration & dosage), Carboplatin (adverse effects), Chemotherapy, Adjuvant, Cystadenocarcinoma, Serous (drug therapy), Cystadenocarcinoma, Serous (epidemiology), Doxorubicin (administration & dosage), Doxorubicin (adverse effects), Doxorubicin (analogs & derivatives), Drug Resistance, Neoplasm (drug effects), Drug-Related Side Effects and Adverse Reactions (epidemiology), Female, Humans, Middle Aged, Ovarian Neoplasms (drug therapy), Ovarian Neoplasms (epidemiology), Paclitaxel (administration & dosage), Paclitaxel (adverse effects), Platinum Compounds (therapeutic use), Polyethylene Glycols (administration & dosage), Polyethylene Glycols (adverse effects), Recurrence.
- MESH :
- chemical , administration & dosage : Carboplatin, Doxorubicin, Paclitaxel, Polyethylene Glycols.
- chemical , adverse effects : Carboplatin, Doxorubicin, Paclitaxel, Polyethylene Glycols.
- chemical , analogs & derivatives : Doxorubicin.
- drug effects : Drug Resistance, Neoplasm.
- drug therapy : Cystadenocarcinoma, Serous, Ovarian Neoplasms.
- epidemiology : Cystadenocarcinoma, Serous, Drug-Related Side Effects and Adverse Reactions, Ovarian Neoplasms.
- chemical , therapeutic use : Platinum Compounds.
- Adult, Aged, Aged, 80 and over, Chemotherapy, Adjuvant, Female, Humans, Middle Aged, Recurrence.
Abstract
To perform a subset analysis of patients with very platinum-sensitive recurrent ovarian cancer (ROC) enrolled in the phase III CALYPSO trial.
DOI: 10.1016/j.ejca.2014.11.017
PubMed: 25534295
Links to Exploration step
pubmed:25534295Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.</title>
<author><name sortKey="Mahner, Sven" sort="Mahner, Sven" uniqKey="Mahner S" first="Sven" last="Mahner">Sven Mahner</name>
<affiliation><nlm:affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and University Medical Center Hamburg-Eppendorf, Germany. Electronic address: Sven.Mahner@gmx.de.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Meier, Werner" sort="Meier, Werner" uniqKey="Meier W" first="Werner" last="Meier">Werner Meier</name>
<affiliation><nlm:affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and Evangelisches Krankenhaus Düsseldorf, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Du Bois, Andreas" sort="Du Bois, Andreas" uniqKey="Du Bois A" first="Andreas" last="Du Bois">Andreas Du Bois</name>
<affiliation><nlm:affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and Kliniken Essen-Mitte, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Brown, Chris" sort="Brown, Chris" uniqKey="Brown C" first="Chris" last="Brown">Chris Brown</name>
<affiliation><nlm:affiliation>ANZGOG-NHMRC, Sydney, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lorusso, Domenica" sort="Lorusso, Domenica" uniqKey="Lorusso D" first="Domenica" last="Lorusso">Domenica Lorusso</name>
<affiliation><nlm:affiliation>Multicenter Italian Trials in Ovarian Cancer and gynecologic malignancies group (MITO) and Istituto Nazionale dei Tumori, Milan, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dell Anna, Tiziana" sort="Dell Anna, Tiziana" uniqKey="Dell Anna T" first="Tiziana" last="Dell'Anna">Tiziana Dell'Anna</name>
<affiliation><nlm:affiliation>Mario Negri Gynecologic Oncology Group (MANGO) and Ospedale San Gerardo, Monza, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cretin, Jacques" sort="Cretin, Jacques" uniqKey="Cretin J" first="Jacques" last="Cretin">Jacques Cretin</name>
<affiliation><nlm:affiliation>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Clinique Valdegourue, Nimes, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Havsteen, Hanne" sort="Havsteen, Hanne" uniqKey="Havsteen H" first="Hanne" last="Havsteen">Hanne Havsteen</name>
<affiliation><nlm:affiliation>Nordic Society of Gynecological Oncology (NSGO) and Copenhagen University, Copenhagen, Denmark.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bessette, Paul" sort="Bessette, Paul" uniqKey="Bessette P" first="Paul" last="Bessette">Paul Bessette</name>
<affiliation><nlm:affiliation>National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) and Universite de Sherbrooke, Sherbrooke, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zeimet, Alain G" sort="Zeimet, Alain G" uniqKey="Zeimet A" first="Alain G" last="Zeimet">Alain G. Zeimet</name>
<affiliation><nlm:affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie Österreich (AGO-Austria) and Innsbruck University, Innsbruck, Austria.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vergote, Ignace" sort="Vergote, Ignace" uniqKey="Vergote I" first="Ignace" last="Vergote">Ignace Vergote</name>
<affiliation><nlm:affiliation>European Organisation for Research and Treatment of Cancer (EORTC) and University Hospital Leuven, Leuven, Belgium.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vasey, Paul" sort="Vasey, Paul" uniqKey="Vasey P" first="Paul" last="Vasey">Paul Vasey</name>
<affiliation><nlm:affiliation>Australia New Zealand Gynecological Oncology Group (ANZGOG) and Wesley Medical Centre, Brisbane, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name>
<affiliation><nlm:affiliation>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universite Paris Descartes, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gladieff, Laurence" sort="Gladieff, Laurence" uniqKey="Gladieff L" first="Laurence" last="Gladieff">Laurence Gladieff</name>
<affiliation><nlm:affiliation>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Institut Claudius Regaud, Toulouse, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ferrero, Annamaria" sort="Ferrero, Annamaria" uniqKey="Ferrero A" first="Annamaria" last="Ferrero">Annamaria Ferrero</name>
<affiliation><nlm:affiliation>Mario Negri Gynecologic Oncology Group (MANGO) and Ospedale Ordine Mauriziano di Torino, Turin, Italy.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25534295</idno>
<idno type="pmid">25534295</idno>
<idno type="doi">10.1016/j.ejca.2014.11.017</idno>
<idno type="wicri:Area/PubMed/Corpus">003020</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003020</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.</title>
<author><name sortKey="Mahner, Sven" sort="Mahner, Sven" uniqKey="Mahner S" first="Sven" last="Mahner">Sven Mahner</name>
<affiliation><nlm:affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and University Medical Center Hamburg-Eppendorf, Germany. Electronic address: Sven.Mahner@gmx.de.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Meier, Werner" sort="Meier, Werner" uniqKey="Meier W" first="Werner" last="Meier">Werner Meier</name>
<affiliation><nlm:affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and Evangelisches Krankenhaus Düsseldorf, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Du Bois, Andreas" sort="Du Bois, Andreas" uniqKey="Du Bois A" first="Andreas" last="Du Bois">Andreas Du Bois</name>
<affiliation><nlm:affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and Kliniken Essen-Mitte, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Brown, Chris" sort="Brown, Chris" uniqKey="Brown C" first="Chris" last="Brown">Chris Brown</name>
<affiliation><nlm:affiliation>ANZGOG-NHMRC, Sydney, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lorusso, Domenica" sort="Lorusso, Domenica" uniqKey="Lorusso D" first="Domenica" last="Lorusso">Domenica Lorusso</name>
<affiliation><nlm:affiliation>Multicenter Italian Trials in Ovarian Cancer and gynecologic malignancies group (MITO) and Istituto Nazionale dei Tumori, Milan, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dell Anna, Tiziana" sort="Dell Anna, Tiziana" uniqKey="Dell Anna T" first="Tiziana" last="Dell'Anna">Tiziana Dell'Anna</name>
<affiliation><nlm:affiliation>Mario Negri Gynecologic Oncology Group (MANGO) and Ospedale San Gerardo, Monza, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cretin, Jacques" sort="Cretin, Jacques" uniqKey="Cretin J" first="Jacques" last="Cretin">Jacques Cretin</name>
<affiliation><nlm:affiliation>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Clinique Valdegourue, Nimes, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Havsteen, Hanne" sort="Havsteen, Hanne" uniqKey="Havsteen H" first="Hanne" last="Havsteen">Hanne Havsteen</name>
<affiliation><nlm:affiliation>Nordic Society of Gynecological Oncology (NSGO) and Copenhagen University, Copenhagen, Denmark.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bessette, Paul" sort="Bessette, Paul" uniqKey="Bessette P" first="Paul" last="Bessette">Paul Bessette</name>
<affiliation><nlm:affiliation>National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) and Universite de Sherbrooke, Sherbrooke, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zeimet, Alain G" sort="Zeimet, Alain G" uniqKey="Zeimet A" first="Alain G" last="Zeimet">Alain G. Zeimet</name>
<affiliation><nlm:affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie Österreich (AGO-Austria) and Innsbruck University, Innsbruck, Austria.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vergote, Ignace" sort="Vergote, Ignace" uniqKey="Vergote I" first="Ignace" last="Vergote">Ignace Vergote</name>
<affiliation><nlm:affiliation>European Organisation for Research and Treatment of Cancer (EORTC) and University Hospital Leuven, Leuven, Belgium.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vasey, Paul" sort="Vasey, Paul" uniqKey="Vasey P" first="Paul" last="Vasey">Paul Vasey</name>
<affiliation><nlm:affiliation>Australia New Zealand Gynecological Oncology Group (ANZGOG) and Wesley Medical Centre, Brisbane, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name>
<affiliation><nlm:affiliation>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universite Paris Descartes, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gladieff, Laurence" sort="Gladieff, Laurence" uniqKey="Gladieff L" first="Laurence" last="Gladieff">Laurence Gladieff</name>
<affiliation><nlm:affiliation>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Institut Claudius Regaud, Toulouse, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ferrero, Annamaria" sort="Ferrero, Annamaria" uniqKey="Ferrero A" first="Annamaria" last="Ferrero">Annamaria Ferrero</name>
<affiliation><nlm:affiliation>Mario Negri Gynecologic Oncology Group (MANGO) and Ospedale Ordine Mauriziano di Torino, Turin, Italy.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">European journal of cancer (Oxford, England : 1990)</title>
<idno type="eISSN">1879-0852</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Carboplatin (administration & dosage)</term>
<term>Carboplatin (adverse effects)</term>
<term>Chemotherapy, Adjuvant</term>
<term>Cystadenocarcinoma, Serous (drug therapy)</term>
<term>Cystadenocarcinoma, Serous (epidemiology)</term>
<term>Doxorubicin (administration & dosage)</term>
<term>Doxorubicin (adverse effects)</term>
<term>Doxorubicin (analogs & derivatives)</term>
<term>Drug Resistance, Neoplasm (drug effects)</term>
<term>Drug-Related Side Effects and Adverse Reactions (epidemiology)</term>
<term>Female</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Ovarian Neoplasms (drug therapy)</term>
<term>Ovarian Neoplasms (epidemiology)</term>
<term>Paclitaxel (administration & dosage)</term>
<term>Paclitaxel (adverse effects)</term>
<term>Platinum Compounds (therapeutic use)</term>
<term>Polyethylene Glycols (administration & dosage)</term>
<term>Polyethylene Glycols (adverse effects)</term>
<term>Recurrence</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Carboplatin</term>
<term>Doxorubicin</term>
<term>Paclitaxel</term>
<term>Polyethylene Glycols</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Carboplatin</term>
<term>Doxorubicin</term>
<term>Paclitaxel</term>
<term>Polyethylene Glycols</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Doxorubicin</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Drug Resistance, Neoplasm</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cystadenocarcinoma, Serous</term>
<term>Ovarian Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Cystadenocarcinoma, Serous</term>
<term>Drug-Related Side Effects and Adverse Reactions</term>
<term>Ovarian Neoplasms</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Platinum Compounds</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Chemotherapy, Adjuvant</term>
<term>Female</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Recurrence</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To perform a subset analysis of patients with very platinum-sensitive recurrent ovarian cancer (ROC) enrolled in the phase III CALYPSO trial.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25534295</PMID>
<DateCreated><Year>2015</Year>
<Month>02</Month>
<Day>04</Day>
</DateCreated>
<DateCompleted><Year>2015</Year>
<Month>04</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0852</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>51</Volume>
<Issue>3</Issue>
<PubDate><Year>2015</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>European journal of cancer (Oxford, England : 1990)</Title>
<ISOAbbreviation>Eur. J. Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.</ArticleTitle>
<Pagination><MedlinePgn>352-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2014.11.017</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0959-8049(14)01142-3</ELocationID>
<Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To perform a subset analysis of patients with very platinum-sensitive recurrent ovarian cancer (ROC) enrolled in the phase III CALYPSO trial.</AbstractText>
<AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">The international non-inferiority trial enrolled women with ROC that relapsed >6 months following first- or second-line platinum- and paclitaxel-based therapies. Patients were randomised to CD [carboplatin-pegylated liposomal doxorubicin (PLD)] or CP (carboplatin-paclitaxel) and stratified by treatment-free interval (TFI). In this analysis, patients with a TFI>24 months were analysed separately for progression free survival (PFS), the primary endpoint of CALYPSO, overall survival (OS) and safety.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 259 very platinum-sensitive patients were included (n=131, CD; n=128, CP). Median PFS was 12.0 months for the CD arm and 12.3 months for CP [HR=1.05 (95% CI, 0.79-1.40); P=0.73 for superiority] and median OS was 40.2 months for CD and 43.9 for CP [HR=1.18 (95% CI 0.85-1.63); P=0.33 for superiority]. Overall response rates were 42% and 38%, respectively (P=0.46). Toxicities were more common with CP versus CD, including grade 3/4 neutropenia (40.8% versus 27.5%; P=0.025), nausea (4.8% versus 3.1%; P=0.47), allergic reaction (8% versus 3.1%; P=0.082) sensory neuropathy (4.8% versus 2.3%; P=0.27) and grade 2 alopecia (88% versus 9.2%; P<0.001). Grade 3/4 thrombocytopenia (12.2% versus 3.2%; P=0.007) and mucositis (2.3% versus 0%; P=0.089) were more common with CD. Grade 3/4 hand-foot syndrome occurred rarely with CD (3 patients versus 0 in CP arm; P=0.089).</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CP and CD were equally effective treatment regimens for patients with very platinum-sensitive ROC. The favourable risk-benefit profile suggests carboplatin-PLD as treatment of choice for these patients.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mahner</LastName>
<ForeName>Sven</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and University Medical Center Hamburg-Eppendorf, Germany. Electronic address: Sven.Mahner@gmx.de.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Meier</LastName>
<ForeName>Werner</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and Evangelisches Krankenhaus Düsseldorf, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>du Bois</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie, AGO Study Group (AGO) and Kliniken Essen-Mitte, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Brown</LastName>
<ForeName>Chris</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>ANZGOG-NHMRC, Sydney, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lorusso</LastName>
<ForeName>Domenica</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Multicenter Italian Trials in Ovarian Cancer and gynecologic malignancies group (MITO) and Istituto Nazionale dei Tumori, Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dell'Anna</LastName>
<ForeName>Tiziana</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Mario Negri Gynecologic Oncology Group (MANGO) and Ospedale San Gerardo, Monza, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cretin</LastName>
<ForeName>Jacques</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Clinique Valdegourue, Nimes, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Havsteen</LastName>
<ForeName>Hanne</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Nordic Society of Gynecological Oncology (NSGO) and Copenhagen University, Copenhagen, Denmark.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bessette</LastName>
<ForeName>Paul</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) and Universite de Sherbrooke, Sherbrooke, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zeimet</LastName>
<ForeName>Alain G</ForeName>
<Initials>AG</Initials>
<AffiliationInfo><Affiliation>Arbeitsgemeinschaft Gynäkologische Onkologie Österreich (AGO-Austria) and Innsbruck University, Innsbruck, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vergote</LastName>
<ForeName>Ignace</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>European Organisation for Research and Treatment of Cancer (EORTC) and University Hospital Leuven, Leuven, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vasey</LastName>
<ForeName>Paul</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Australia New Zealand Gynecological Oncology Group (ANZGOG) and Wesley Medical Centre, Brisbane, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pujade-Lauraine</LastName>
<ForeName>Eric</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Universite Paris Descartes, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gladieff</LastName>
<ForeName>Laurence</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Institut Claudius Regaud, Toulouse, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ferrero</LastName>
<ForeName>Annamaria</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Mario Negri Gynecologic Oncology Group (MANGO) and Ospedale Ordine Mauriziano di Torino, Turin, Italy.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>12</Month>
<Day>17</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Eur J Cancer</MedlineTA>
<NlmUniqueID>9005373</NlmUniqueID>
<ISSNLinking>0959-8049</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017671">Platinum Compounds</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C506643">liposomal doxorubicin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>30IQX730WE</RegistryNumber>
<NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>80168379AG</RegistryNumber>
<NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>BG3F62OND5</RegistryNumber>
<NameOfSubstance UI="D016190">Carboplatin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>P88XT4IS4D</RegistryNumber>
<NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016190" MajorTopicYN="N">Carboplatin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018284" MajorTopicYN="N">Cystadenocarcinoma, Serous</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017671" MajorTopicYN="N">Platinum Compounds</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CALYPSO</Keyword>
<Keyword MajorTopicYN="N">Carboplatin</Keyword>
<Keyword MajorTopicYN="N">Ovarian cancer</Keyword>
<Keyword MajorTopicYN="N">Paclitaxel</Keyword>
<Keyword MajorTopicYN="N">Pegylated liposomal doxorubicin</Keyword>
<Keyword MajorTopicYN="N">Very platinum-sensitive</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2014</Year>
<Month>11</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2014</Year>
<Month>11</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>12</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>12</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>4</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25534295</ArticleId>
<ArticleId IdType="pii">S0959-8049(14)01142-3</ArticleId>
<ArticleId IdType="doi">10.1016/j.ejca.2014.11.017</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003020 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003020 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:25534295 |texte= Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25534295" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |